RC148 Injection + pemetrexed disodium for injection + carboplatin injection

"RC148 Injection + pemetrexed disodium for injection + carboplatin injection" is an investigational combination regimen being evaluated for the first-line treatment of advanced non-squamous non-small cell lung cancer (NSCLC) without actionable genomic alterations. The regimen combines RC148 (also known as ABBV-1480), a novel humanized IgG1 silenced bispecific antibody targeting Programmed Cell Death-1 (PD-1) and Vascular Endothelial Growth Factor (VEGF), with standard platinum-based chemotherapy agents pemetrexed disodium and carboplatin. RC148 simultaneously blocks immune checkpoint evasion and tumor angiogenesis, while its silenced Fc effector function is designed to minimize antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) to reduce toxicity. Pemetrexed disodium is a folate analog metabolic inhibitor, and carboplatin is an alkylating-like platinum chemotherapy agent. The combination is developed by RemeGen in collaboration with AbbVie, which holds exclusive rights to develop, manufacture, and commercialize RC148 outside of Greater China.

Other names

ABBV-1480 + pemetrexed + carboplatinABBV-1480 + pemetrexed disodium + carboplatinRC148 + carboplatin + pemetrexedRC148 + pemetrexed + carboplatinRC148 + pemetrexed disodium + carboplatinRC148 plus Carboplatin and pemetrexedRC-148 plus Carboplatin and pemetrexedRC 148 plus Carboplatin and pemetrexed